关节外表现及合并症对强直性脊柱炎首个TNF抑制剂药物留存的影响
结果发现,前葡萄膜炎与更优的TNFi药物留存相关(HR 0.72;0.62~0.83),银屑病与更差的留存相关(HR 1.48;1.18~1.86),而炎症性肠病(IBD)不影响留存;关节外表现与合并症对留存的影响幅度相近。
要点
- 前葡萄膜炎与更优的TNFi药物留存相关,银屑病与更差的留存相关。
- IBD未影响AS患者首个TNFi的药物留存。
- 合并症与社会经济因素对TNFi留存的影响幅度与关节外表现相近。
核心结论
- 在AS中,前葡萄膜炎和银屑病(而非IBD)影响首个TNFi的药物留存。
- 合并症与社会经济因素对TNFi药物留存的影响幅度与关节外SpA表现相近,临床应予重视。
研究设计与样本
- 通过关联另外五个国家登记库,确定TNFi启用前关节外SpA表现、合并症及社会经济状况,并计算各因素停药的风险比及其校正值。
主要发现
- 共2577例AS患者(71%为男性)在研究期内首次启用TNFi。
- 27%有前葡萄膜炎史,6%有银屑病,7%有IBD。
- 前葡萄膜炎与更优的TNFi药物留存相关(HR 0.72;0.62~0.83)。
- 银屑病与更差的TNFi药物留存相关(HR 1.48;1.18~1.86)。
- IBD未影响TNFi药物留存,关节外表现对留存的影响幅度与合并症相近。
关键数值与推荐
- 前葡萄膜炎与更优TNFi药物留存相关:HR 0.72;0.62~0.83。
- 银屑病与更差TNFi药物留存相关:HR 1.48;1.18~1.86。
- IBD未影响TNFi药物留存。
- 纳入2577例AS患者,71%为男性;27%有前葡萄膜炎史,6%有银屑病,7%有IBD。
临床怎么用
- 临床评估AS患者启用首个TNFi时,应关注前葡萄膜炎、银屑病等关节外表现对药物留存的潜在影响。
- 合并症与社会经济因素对TNFi留存的影响幅度与关节外表现相近,临床实践中应予以重视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the impact of extra-articular spondyloarthritis (SpA) manifestations (anterior uveitis, psoriasis and inflammatory bowel disease (IBD)), and of comorbidities, on tumour necrosis factor alpha inhibitor (TNFi) drug retention in ankylosing spondylitis (AS). METHODS: We identified all bio-naïve patients with AS starting a first ever TNFi July 2006 to December 2015 from the Swedish Rheumatology Quality register and followed these from treatment start through December 2015. We determined the presence of extra-articular SpA-manifestations, comorbidities (cardiovascular disease, affective disease, diabetes, malignancies, chronic lung disease and kidney disease) and socioeconomic status before TNFi start, through linkage to five other national registers, and calculated, for each factor, crude and adjusted HRs for discontinuing the TNFi. RESULTS: 2577 patients with AS (71% men) started a first TNFi during the study period. 27% had a history of anterior uveitis, 6% psoriasis and 7% IBD. Anterior uveitis was associated with a superior TNFi drug retention (HR 0.72; 0.62 to 0.83), psoriasis with an inferior (HR 1.48; 1.18 to 1.86), whereas IBD did not affect TNFi drug retention. The effect of the SpA manifestations on TNFi drug retention was of a similar magnitude to that of the comorbidities. CONCLUSIONS: In AS, anterior uveitis and psoriasis, but not IBD, affect TNFi drug retention. Possible explanations include differential effects of TNFi on these extra-articular SpA manifestations, or inherent differences in AS, associated with the inflammatory phenotype. Further, comorbidities and socioeconomy affect TNFi drug retention to a similar magnitude as the SpA manifestations, and should, as such, receive due attention in clinical practice.
引用
- Lindström U, Olofsson T, Wedrén S, et al. Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study. RMD Open. 2018. PMID: 30402269. doi:10.1136/rmdopen-2018-000762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。